Skip to content
Back to meeting Original
DrJorgeB_George· @DrJorgeBarriuso · X·· 3 days agoScore70

KRAS

Body · original

Nice update of the RASolute 302 at #ESMO26
Looking at the outcomes. Although small numbers, are we facing a roadblock with the KRAS G12R variant?
Represents between 12-15%
Could protein degraders be a viable alternative?
#ESMOAmbassadors @myESMO @GrupoTTD

74 views · 2 likes · 0 reposts · 0 replies

Conference abstracts
2683Pmatched by NSCLC, metastatic

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org

Source: DrJorgeB_George · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.